Your browser doesn't support javascript.
loading
SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1.
Law, John Lok Man; Logan, Michael; Joyce, Michael A; Landi, Abdolamir; Hockman, Darren; Crawford, Kevin; Johnson, Janelle; LaChance, Gerald; Saffran, Holly A; Shields, Justin; Hobart, Eve; Brassard, Raelynn; Arutyunova, Elena; Pabbaraju, Kanti; Croxen, Matthew; Tipples, Graham; Lemieux, M Joanne; Tyrrell, D Lorne; Houghton, Michael.
Afiliación
  • Law JLM; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada. Electronic address: LLAW@ualberta.ca.
  • Logan M; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
  • Joyce MA; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
  • Landi A; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
  • Hockman D; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
  • Crawford K; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
  • Johnson J; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
  • LaChance G; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
  • Saffran HA; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
  • Shields J; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
  • Hobart E; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
  • Brassard R; Department of Biochemistry, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
  • Arutyunova E; Department of Biochemistry, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
  • Pabbaraju K; Alberta Precision Laboratories, Edmonton, Canada.
  • Croxen M; Alberta Precision Laboratories, Edmonton, Canada.
  • Tipples G; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada; Alberta Precision Laboratories, Edmonton, Canada.
  • Lemieux MJ; Department of Biochemistry, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
  • Tyrrell DL; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
  • Houghton M; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada. Electronic address: michael.houghton@ualberta.ca.
Vaccine ; 39(40): 5769-5779, 2021 09 24.
Article en En | MEDLINE | ID: mdl-34481699

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / COVID-19 Límite: Humans Idioma: En Revista: Vaccine Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / COVID-19 Límite: Humans Idioma: En Revista: Vaccine Año: 2021 Tipo del documento: Article